Minster Pharmaceuticals is a drug development company specialising in compounds for the treatment of neurological and psychiatric conditions. The company, whose management has extensive scientific, regulatory and project management experience, has acquired from GlaxoSmithKline the worldwide development rights to two compounds, tonabersat and sabcomeline.

The company benefits from collaborations with world-class academic centres and clinicians and also from a team of internationally renowned specialist advisors.

Minster joined the AIM market of the London Stock Exchange in February 2005 and trades under the symbol MPM.